1-哌嗪乙醇硝酸酯 | 52808-35-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-哌嗪乙醇硝酸酯
• 英文名称: 4-<2-Hydroxyethyl>-piperazin-nitrat
• 英文别名: 1-(2-nitryloxy-ethyl)-piperazine；2-(Piperazin-1-yl)ethyl nitrate；2-piperazin-1-ylethyl nitrate
• CAS: 52808-35-2
• 化学式: C₆H₁₃N₃O₃
• 分子量: 175.188
• InChiKey: OLZVGHGZAVZUPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  70.3
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  1-哌嗪乙醇硝酸酯 、 1-chloroacetyl-6-oxo-1,2,3,4-tetrahydro-6H-pyrimido<2,1-b>quinazoline 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 192.0h， 以41%的产率得到1-[4-(2-(nitrooxyethyl)piperazino)acetyl]-6-oxo-1,2,3,4-tetrahydro-6H-pyrimido[2,1-b]quinazoline
  参考文献：
  名称：

  Korzycka, Polish Journal of Chemistry, 2003, vol. 77, # 5, p. 557 - 563

  摘要：

  DOI：
• 作为产物：
  描述：

  N-羟乙基哌嗪 在 硝酸 、 乙酸酐 、 溶剂黄146 作用下， 反应 1.0h， 生成 1-哌嗪乙醇硝酸酯
  参考文献：
  名称：

  Korzycka, Polish Journal of Chemistry, 2003, vol. 77, # 5, p. 557 - 563

  摘要：

  DOI：

文献信息

• NITRIC OXIDE-RELEASING PRODRUG MOLECULE
  申请人：Zhejiang Huahai Pharmaceutical Co., Ltd

  公开号：EP3348548A1

  公开（公告）日：2018-07-18

  Provided are a type of compounds that can be used for treating cardiovascular diseases and compositions containing the compounds. The compounds and the compositions can improve lipid metabolism disorders by increasing high-density lipoprotein cholesterol in blood; in addition, the compounds and the compositions can also release nitric oxide, and reduce the onset risk of cardiovascular diseases by means of relaxing blood vessels, lowering blood pressure, inhibiting platelet adhesion and aggregation and maintaining vascular tension, and thus play an important role in preventing and treating the occurrence and development of cardiovascular diseases.

  提供一种可用于治疗心血管疾病的化合物和含有该化合物的组合物。该化合物和组合物可以通过增加血液中的高密度脂蛋白胆固醇来改善脂质代谢紊乱；此外，该化合物和组合物还可以释放一氧化氮，并通过放松血管、降低血压、抑制血小板粘附和聚集以及维持血管张力来降低心血管疾病的发病风险，从而在预防和治疗心血管疾病的发生和发展中发挥重要作用。
• Nitric oxide-releasing prodrug molecule of substituted quinazolines
  申请人：ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD

  公开号：US10456405B2

  公开（公告）日：2019-10-29

  Provided are a compound of the formula below, and a pharmaceutically acceptable salt or stereoisomer thereof that can be used for treating cardiovascular diseases and compositions containing the compounds. The compounds, a pharmaceutically acceptable salt or stereoisomer thereof and the compositions can improve lipid metabolism disorders by increasing high-density lipoprotein cholesterol in blood; in addition, the compounds, a pharmaceutically acceptable salt or stereoisomer thereof and the compositions can also release nitric oxide, and reduce the onset risk of cardiovascular diseases by means of relaxing blood vessels, lowering blood pressure, inhibiting platelet adhesion and aggregation and maintaining vascular tension, and thus play an important role in preventing and treating the occurrence and development of cardiovascular diseases.

  本发明提供了可用于治疗心血管疾病的下式化合物及其药学上可接受的盐或立体异构体以及含有该化合物的组合物。该化合物、其药学上可接受的盐或立体异构体及其组合物可以通过增加血液中的高密度脂蛋白胆固醇来改善脂质代谢紊乱；此外，该化合物、其药学上可接受的盐或立体异构体及其组合物还可以释放一氧化氮，通过舒张血管、降低血压、抑制血小板粘附和聚集、维持血管张力等作用来降低心血管疾病的发病风险，从而在预防和治疗心血管疾病的发生和发展中发挥重要作用。
• Design of Barbiturate–Nitrate Hybrids that Inhibit MMP-9 Activity and Secretion
  作者：Jun Wang、Shane O’Sullivan、Shona Harmon、Ray Keaveny、Marek W. Radomski、Carlos Medina、John F. Gilmer

  DOI：10.1021/jm201352k

  日期：2012.3.8

  We describe a new type of barbiturate-based matrix metalloproteinase (MMP) inhibitor incorporating a nitric oxide (NO) donor/mimetic group (series 1). The compounds were designed to inhibit MMP at enzyme level and to attenuate MMP-9 secretion arising from inflammatory signaling. To detect effects related to the nitrate, we prepared and studied an analogous series of barbiturate C5-alkyl alcohols that were unable to release NO (series 2). Both series inhibited recombinant human MMP-2/9 activity with nanomolar potency. Series 1 consistently inhibited the secretion of MMP-9 from TNF alpha/IL1 beta stimulated Caco-2 cells at 10 mu M, which could be attributed to NO related effects because the non-nitrate panel did not affect enzyme levels. Several compounds from series 1 (10 mu M) inhibited tumor cell invasion but none from the non-nitrate panel did. The work shows that MMP-inhibitory barbiturates are suitable scaffolds for hybrid design, targeting additional facets of MMP pathophysiology, with potential to improve risk-benefit ratios.
• Korzycka, Polish Journal of Chemistry, 2003, vol. 77, # 5, p. 557 - 563
  作者：Korzycka

  DOI：——

  日期：——